| dc.contributor.author | Fukui, Masao | |
| dc.contributor.author | Kawaguchi, Kohei | |
| dc.contributor.author | Matsuura, Hiroaki | |
| dc.date.accessioned | 2020-07-14T19:55:41Z | |
| dc.date.available | 2020-07-14T19:55:41Z | |
| dc.date.issued | 2020-04-22 | |
| dc.identifier.uri | https://doi.org/10.1101/2020.04.13.20064287 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/2052 | |
| dc.description.abstract | In the middle of the global COVID-19 pandemic, the BCG hypothesis, the prevalence and severity of the COVID-19 outbreak seems to be correlated with whether a country has a universal coverage of Bacillus-Calmette-Guerin (BCG), a vaccine for tuberculosis disease (TB), has emerged and attracted the attention of scientific community and media outlets. However, all existing claims are based on cross-country correlations that do not exclude the possibility of spurious correlation. We merged country-age-level case statistics with the start/termination years of BCG vaccination policy and conducted a regression discontinuity and difference-in-difference analysis. The results do not support the BCG hypothesis. | en_US |
| dc.language | English | en_US |
| dc.subject | BCG Vaccine | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Coronavirus Infections | en_US |
| dc.subject | Outbreak | en_US |
| dc.subject | Therapeutics | en_US |
| dc.title | Does TB Vaccination Reduce COVID-19 Infection?: No Evidence from a Regression Discontinuity Analysis | en_US |
| eihealth.country | Global (WHO/OMS) | en_US |
| eihealth.category | Public Health Interventions | en_US |
| eihealth.type | Published Article | en_US |
| eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
| dc.relation.ispartofjournal | medRxiv | en_US |
